- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.06. | Innovotech Inc. Announces CFO Transition and Reports 2026 Annual General Meeting Result | 2 | TheNewswire | ||
| 14.05. | Innovotech Inc. Receives Support to Develop Antimicrobial Testing Services and Product Enhancements | 2 | TheNewswire | ||
| 12.05. | Innovotech Inc. Reports Q1 2026 Financial Results and Operational Update | 1 | TheNewswire | ||
| 12.05. | Innovotech reports Q1 results | 1 | Seeking Alpha | ||
| 30.04. | Fendx Technologies Inc (2): Fendx hires Innovotech for Foley regulatory pathway | 8 | Stockwatch | ||
| INNOVOTECH Aktie jetzt für 0€ handeln | |||||
| 30.04. | FendX Technologies Inc.: FendX Engages Innovotech for Regulatory Pathway Assessment of Its Coated Foley Catheter Program | 1.008 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - April 29, 2026) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), a technology company developing surface-protection... ► Artikel lesen | |
| 15.04. | Innovotech Inc. Begins Trading on OTCQB Under Symbol IOTCF, Expanding Access for U.S. Investors | 1 | TheNewswire | ||
| 01.04. | Innovotech Inc. Reports Fourth Quarter and Full-Year 2025 Financial Results | 1 | TheNewswire | ||
| 26.01. | DealFlow Events: Innovotech Inc. Presenting at the 3rd Annual DealFlow Discovery Conference | 342 | ACCESS Newswire | EDMONTON, AB / ACCESS Newswire / January 26, 2026 / Innovotech Inc. (TSXV:IOT), a leading contract research organization providing proprietary antimicrobial testing and advanced laboratory services... ► Artikel lesen |
9 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 37,075 | -3,58 % | Ihre wichtigsten Termine: Frische Zahlen von Ebay, Eli Lill, Allstate, Infineon, Novo Nordisk, Walt Disney | Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine 06:45 Uhr, Deutschland: Basler... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,985 | +0,77 % | H.C. Wainwright reiterates Neutral stock rating on Summit Therapeutics | ||
| COGENT BIOSCIENCES | 39,190 | -5,63 % | Cogent Biosciences, Inc. - 10-Q, Quarterly Report | ||
| SIONNA THERAPEUTICS | 5,190 | +15,33 % | Sionna Therapeutics, Inc.: Sionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides Corporate Update | SION-719 Phase 2a proof-of-concept trial did not achieve key activity endpoint of sweat chloride reduction when added to standard of care; Company is not advancing SION-719 as an add-on to standard... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 361,88 | -1,38 % | Praxis Precision Medicines, Inc. - 10-Q, Quarterly Report | ||
| TANGO THERAPEUTICS | 26,410 | -4,55 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 134,64 | -0,01 % | Apogee Therapeutics: Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates | AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive... ► Artikel lesen | |
| ERASCA | 17,940 | -0,99 % | Erasca, Inc. - 8-K, Current Report | ||
| ALUMIS | 24,550 | -10,82 % | Alumis Inc.: Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis | Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality-of-life improvements and itch... ► Artikel lesen | |
| SEPTERNA | 44,840 | +15,42 % | Septerna, Inc.: Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results | Phase 1 Clinical Trial Ongoing for SEP-479, an Oral Small Molecule PTH1R Agonist SEP-479 Observed Clinical Pharmacokinetic Profile Supports Once-Daily Dosing; SAD / MAD Data Expected in Q1 2027 Cash... ► Artikel lesen | |
| BICARA THERAPEUTICS | 24,775 | -10,66 % | Bicara Therapeutics Inc.: Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth | President & Chief Operating Officer Ryan Cohlhepp, Pharm.D. appointed President & Chief Executive Officer effective January 2027 Claire Mazumdar, Ph.D., MBA to transition to Vice Chair of the Board... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 16,170 | -6,80 % | MoonLake Immunotherapeutics AG: MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial | Phase 3 IZAR-1 trial in bio-naïve patients met all clinical endpoints at Week 16 for 60 mg sonelokimabThe primary endpoint of ACR50 was met with a high response of 42.1% for sonelokimab's 60 mg with... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 57,95 | -2,47 % | Guggenheim lowers Enliven Therapeutics stock price target to $78 | ||
| VERA THERAPEUTICS | 30,900 | -2,15 % | Vera Therapeutics GAAP EPS of -$1.52 beats by $0.04 | ||
| EVOTEC | 3,706 | +1,37 % | Übernahmekandidaten! Steyr Motors nach 20 %-Sprung! RE Royalties spannend! Und was macht Evotec? | Um 20 % ist die Aktie von Steyr Motors in der vergangenen Woche kurzzeitig explodiert. Grund waren Übernahmespekulationen durch einen Drohnen- und Robotikspezialisten aus den USA. Die Gespräche wurden... ► Artikel lesen |
Das Unternehmen INNOVOTECH INC kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INNOVOTECH INC finden Sie auf Wallstreet Online.